NZYM B Novozymes A/S Class B

Major shareholder announcement

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.

Per November 21, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,464,124 shares, corresponding to 5.01% (previously 4.94%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments is 5.15% (previously 5.08%).

Attachments



EN
25/11/2024

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 21, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,464,124 shares, corresponding to 5.01% (previously 4.94%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instrumen...

November 25, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

November 20, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis will host an educational conference call on Energy on Decemb...

Novonesis will host an educational conference call on Energy on December 18 Novonesis will host a spotlight educational session on our Energy activities which is part of Planetary Health Biosolutions. We will share insights about the industry, its development, and Novonesis’ integral part of the industry’s value chain. The session will be hosted as a conference call on December 18 at 15:00 CET. To join the live webcast, please click . To register and receive access details for the conference call, please click . Attachment

November 18, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 11, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,180,630 shares, corresponding to 4.94% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instr...

November 13, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Q3 update: Novonesis delivers strong Q3 results and now expects full-y...

Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%. COPENHAGEN, Denmark – November 7, 2024. Novonesis delivers 9% organic sales growth, in the fir...

November 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch